Takeda Pharmaceutical Company Limited (TAK) Competitors & Peers
The 5 largest companies in the same industry as Takeda Pharmaceutical Company Limited, by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| JHPCY | Peer | $12.25 | P/E 37.1RSI 35Cap 81.3 B |
| GDERF | Peer | $228.30 | P/E 62.5RSI 56Cap 50.8 B |
| GALDY | Peer | $45.61 | P/E 53.5RSI 46Cap 45.5 B |
| TKPHF | Peer | $42.77 | RSI 49Cap 59.7 B |
| TEVJF | Peer | $38.98 | P/E 65.0RSI 90Cap 45.4 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- ARWRPartner
Arrowhead partners with Takeda on fazirsiran for liver disease.
Model-inferred, unverified — treat as a lead, not evidence - PHVSCompetitor
Pharvaris's oral HAE candidates compete with Takeda's approved injectable HAE therapies.
Model-inferred, unverified — treat as a lead, not evidence - SUPNCompetitor
Supernus's Qelbree competes with Takeda's dominant stimulant ADHD drug Vyvanse.
Model-inferred, unverified — treat as a lead, not evidence